METROPOLITAN Hospital
- Address
- Ethnarchi Makariou 11, 185 47 Athens, Greece
Cardiovascular Diseases
At METROPOLITAN Hospital researchers are evaluating innovative approaches to lower heart risk, including a study that tests a novel RNA‑interference therapy to prevent major adverse cardiovascular events in patients at high risk for atherosclerosis.
- Primary prevention of atherosclerotic cardiovascular disease
- Inclisiran as a lipid‑lowering agent
- Reduction of cardiovascular death, myocardial infarction, and stroke
- Management of high‑risk primary prevention patients
- Integration of cardiovascular biomarkers in trial design
The work supports Greece’s commitment to advancing cardiovascular health across Europe.
Hormonal Diseases
Clinical investigations at the site focus on HR‑positive/HER2‑negative breast cancer, exploring personalized treatment strategies for both premenopausal women with high‑risk disease and patients whose cancer has progressed after CDK4/6 inhibition.
- Gene‑expression guided adjuvant chemotherapy decisions
- Combination of PI3K pathway inhibitors with endocrine therapy
- Targeted therapy for PIK3CA‑mutated tumors
- Overcoming resistance to CDK4/6 inhibitors
- Tailored approaches for young women with early breast cancer
Two investigators lead these studies, aiming to improve outcomes and quality of life for women battling advanced breast cancer.
Neoplasms
The oncology program at METROPOLITAN Hospital includes trials for non‑small cell lung cancer patients, specifically those with KRAS p.G12C mutations and PD‑L1‑negative disease, comparing targeted agents against immunotherapy‑based regimens.
- KRAS G12C‑positive advanced NSCLC
- Sotorasib versus pembrolizumab combined with chemotherapy
- Front‑line platinum doublet therapy with novel agents
- Radiation and chemotherapy combinations for unresectable stage III disease
- Assessment of progression‑free and overall survival endpoints
These trials contribute to global efforts to expand treatment options for patients with difficult‑to‑treat lung cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 53 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 53 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Amgen Inc.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in METROPOLITAN Hospital
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 53 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2019-06-26 | 2024-10-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.